MANKATO — As Blue Earth County prepares to set its 2026 tax levy, preliminary numbers suggest good news for farmers and bad ...

When three patients die after taking a cutting-edge drug, most companies hit the brakes. Not Sarepta Therapeutics. The ...

The death of a third patient tied to a Sarepta Therapeutics gene therapy this year sent the company’s shares nosediving 36% Friday, halting the momentum the stock generated just a day earlier after ...

Sarepta Therapeutics announced late Friday evening that it will not comply with the Food and Drug Administration's ...

Drugmaker Sarepta Therapeutics said it won’t comply with a request from the FDA to halt all shipments of its gene therapy ...

When men delay or avoid their healthcare needs it can impact women caregivers' health. Catherine Corriveau, with Movember, joins Jennifer Palma to discuss a study put out by UBC.

In a highly unusual move, Cambridge-based Sarepta said late Friday won’t comply with a request from the Food and Drug ...

Elevidys is a gene therapy approved to treat Duchenne muscular dystrophy. Last month, Sarapta halted sales of the therapy for non-ambulatory patients.

The Food and Drug Administration plans to ask Sarepta Therapeutics Inc. to pause shipments of its Elevidys treatment after ...

The Dow Jones Industrial Average slipped on Friday (July 18) amid reports that US President Donald Trump is pushing for ...

A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector.